OneWorld Health to become PATH affiliate

Dec 20 2011NewsGuard 100/100 Score

"PATH and OneWorld Health (OWH) [on Friday] announced that OWH will become an affiliate of PATH, bringing its drug development expertise and experience in neglected infectious diseases to bear on PATH's mission of improving global health through innovation," according to a PATH press release. The press release adds, "By becoming a PATH affiliate, OneWorld Health will be able to scale and accelerate its successful drug development efforts, which include developing a semisynthetic version of artemisinin, a key component in treating malaria, to help provide an affordable, stable source of the drug, alleviate shortages, and meet global demand" (12/16).

http://www.kaiserhealthnews.orgThis article was reprinted from kaiserhealthnews.org with permission from the Henry J. Kaiser Family Foundation. Kaiser Health News, an editorially independent news service, is a program of the Kaiser Family Foundation, a nonpartisan health care policy research organization unaffiliated with Kaiser Permanente.

Posted in: Disease/Infection News | Healthcare News

Tags: , , , , ,

Comments (0)

Suggested Reading

Study provides insights into trends and disparities of neonatal infectious diseases in LMICs
Rutgers study sheds light on how bedaquiline fights drug-resistant tuberculosis
Metagenomic sequencing improves detection of rare pathogens in CNS infections
As California taps pandemic stockpile for bird flu, officials keep close eye on spending
Advanced diagnostic kit developed for detecting highly pathogenic H5N1 avian influenza virus
Breakthrough method sheds light on how immune receptors detect infections
Modified darobactin offers hope for combatting antibiotic-resistant bacteria
Study finds artemisinin resistance in African children with severe malaria

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
(Logout)
Post

Newsletters you may be interested in

See all Newsletters »

Terms

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

Provide Feedback

You might also like...
New biomarker could predict response to IBD treatment